Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04071457
Title S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

multiple myeloma

Therapies

Daratumumab + Lenalidomide + rHuPH20

Lenalidomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.